Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3

The lymphatic vasculature transports extravasated tissue fluid, macromolecules and cells back into the blood circulation. Recent reports have focused on the molecular mechanisms regulating the lymphatic vessels. Vascular endothelial growth factor (VEGF)-C and VEGF-D have been shown to stimulate lymphangiogenesis and their receptor, VEGFR-3, has been linked to human hereditary lymphedema. Here we show that a soluble form of VEGFR-3 is a potent inhibitor of VEGF-C/VEGF-D signaling, and when expressed in the skin of transgenic mice, it inhibits fetal lymphangiogenesis and induces a regression of already formed lymphatic vessels, though the blood vasculature remains normal. Transgenic mice develop a lymphedema-like phenotype characterized by swelling of feet, edema and dermal fibrosis. They survive the neonatal period in spite of a virtually complete lack of lymphatic vessels in several tissues, and later show regeneration of the lymphatic vasculature, indicating that induction of lymphatic regeneration may also be possible in humans.

[1]  E. Fuchs,et al.  Programming gene expression in developing epidermis. , 1994, Development.

[2]  K. Alitalo,et al.  Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. , 1999, Current topics in microbiology and immunology.

[3]  K. Alitalo,et al.  Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis , 1999, British Journal of Cancer.

[4]  Itzhak D. Goldberg,et al.  Regulation of Angiogenesis , 1996, Experientia Supplementum.

[5]  Robert E. Ferrell,et al.  Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema , 2000, Nature Genetics.

[6]  L. Aiello,et al.  Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[7]  K. Alitalo,et al.  VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. , 1999, The American journal of pathology.

[8]  K. Alitalo,et al.  Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[9]  M Aguet,et al.  VEGF is required for growth and survival in neonatal mice. , 1999, Development.

[10]  K. Alitalo,et al.  Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. , 1998, The American journal of pathology.

[11]  R. Crystal,et al.  Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. , 1998, Human gene therapy.

[12]  E C Nice,et al.  Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3. , 2000, European journal of biochemistry.

[13]  N. Ferrara.  Molecular and biological properties of vascular endothelial growth factor , 1999, Journal of Molecular Medicine.

[14]  Y Sakai,et al.  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis , 2022 .

[15]  L. Orci,et al.  Vascular endothelial growth factor‐C‐mediated lymphangiogenesis promotes tumour metastasis , 2001, The EMBO journal.

[16]  Yihai Cao,et al.  Proteolytic processing regulates receptor specificity and activity of VEGF‐C , 1997, The EMBO journal.

[17]  Thomas N. Sato,et al.  Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. , 1999, Science.

[18]  D. Jackson,et al.  LYVE-1, a New Homologue of the CD44 Glycoprotein, Is a Lymph-specific Receptor for Hyaluronan , 1999, The Journal of cell biology.

[19]  J. Peng,et al.  Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. , 1999, Development.

[20]  K. Alitalo,et al.  VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. , 1997, Developmental biology.

[21]  E. Keshet,et al.  A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. , 1998, Development.

[22]  K. Inoue,et al.  Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. , 2000, Cancer research.

[23]  A. Albini,et al.  c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[24]  K. Alitalo,et al.  Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. , 1998, The American journal of pathology.

[25]  P. Carmeliet.  Mechanisms of angiogenesis and arteriogenesis , 2000, Nature Medicine.

[26]  Takuma Sasaki,et al.  Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  M. Dewhirst,et al.  Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[28]  K. Alitalo,et al.  A Recombinant Mutant Vascular Endothelial Growth Factor-C that Has Lost Vascular Endothelial Growth Factor Receptor-2 Binding, Activation, and Vascular Permeability Activities* , 1998, The Journal of Biological Chemistry.

[29]  R. Kendall,et al.  Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Thomas Hawighorst,et al.  Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis , 2001, Nature Medicine.

[31]  M. Karkkainen,et al.  Molecular regulation of lymphangiogenesis and targets for tissue oedema. , 2001, Trends in molecular medicine.

[32]  E. Tschachler,et al.  Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. , 1998, Cancer research.

[33]  K. Alitalo,et al.  Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. , 1998, Science.

[34]  Steven A. Stacker,et al.  VEGF-D promotes the metastatic spread of tumor cells via the lymphatics , 2001, Nature Medicine.

[35]  K. Alitalo,et al.  Vascular endothelial growth factor C induces angiogenesis in vivo. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Kenneth J. Hillan,et al.  Vascular endothelial growth factor is essential for corpus luteum angiogenesis , 1998, Nature Medicine.

[37]  M. Witte,et al.  Lymphangiogenesis: mechanisms, significance and clinical implications. , 1997, EXS.

[38]  K. Alitalo,et al.  VEGF‐C and VEGF‐D expression in neuroendocrine cells and their receptor, VEGFR‐3, in fenestrated blood vessels in human tissues , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  K. Devriendt,et al.  Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. , 2000, American journal of human genetics.

[40]  Risto A. Kauppinen,et al.  1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: Implications for the in vivo detection of apoptosis , 1999, Nature Medicine.

[41]  K. Alitalo,et al.  Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[42]  R. Jain,et al.  Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. , 1997, Science.

[43]  T. Veikkola,et al.  Regulation of angiogenesis via vascular endothelial growth factor receptors. , 2000, Cancer research.

[44]  P. Mortimer,et al.  The pathophysiology of lymphedema , 1998, Cancer.

[45]  K. Alitalo,et al.  Endothelial-specific gene expression directed by the tie gene promoter in vivo. , 1995, Blood.

[46]  K.,et al.  Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[47]  J. Isner,et al.  Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. , 1998, The American journal of pathology.

[48]  Janet Rossant,et al.  Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice , 1995, Nature.